IL-HAGENS-BERMAN-SOBOL
24.6.2020 15:12:13 CEST | Business Wire | Press release
The following is being released by Hagens Berman Sobol Shapiro LLP and Lite DePalma Greenberg LLC.
There are Settlements with Barclays, Bank of America, Citi, HSBC, and JPMorgan (“Settling Defendants”) that impact individuals and institutions that entered into over-the-counter financial instruments directly with Ally, American Express, Bancwest, Bank of New York, BB&T, BBVA, BMO Harris, Capital One, Fifth Third, Goldman Sachs, Harris Financial, Keycorp, M&T, Metlife, Morgan Stanley, Northern Trust, PNC, Regions, State Street, Suntrust, TD Bank, Unionbancal, U.S. Bancorp or Wells Fargo, including their subsidiaries, affiliates, predecessors and successors (“Financial Institutions”). The financial instruments include interest rate swaps, forward rate agreements, asset swaps, collateralized debt obligations, credit default swaps, inflation swaps, total return swaps, options, and floating-rate notes.
The litigation claims that the banks manipulated U.S. Dollar LIBOR during the financial crisis, artificially lowering the rate for their own profit, which resulted in purchasers receiving less interest than they otherwise would have. The Settling Defendants deny all claims of wrongdoing.
There are two groups of individuals and institutions that are impacted by these lawsuits.
Individuals or institutions are included in the Settlements if they: Transacted with a Financial Institution in the United States in a U.S. Dollar-Based Instrument (as defined in the Settlements), which they owned or on which they otherwise received interest based upon U.S. Dollar LIBOR at any time between August 2007 and May 2010.
The Settlements will pay eligible class members who submit valid claims. Additionally, the Settling Defendants will cooperate with the Plaintiffs in their ongoing litigation against the Non-Settling Defendants.
Class Members must submit a Proof of Claim to get a payment. They can submit a Proof of Claim online or by mail. The deadline to submit a Proof of Claim is January 3, 2021 . They are entitled to receive a payment if they have a qualifying transaction with a Financial Institution. At this time, it is unknown how much each class member who submits a valid claim will receive.
If an individual or institution is a member of the class and they do not file a timely claim, they will lose their right to receive money or benefits from the Settlements. If they would like to retain their right to file their own lawsuit against Settling Defendants, they must opt out by August 31, 2020 . If they remain a party to the Settlements, they may object to the Settlements by August 31, 2020 . The Court will hold a hearing on October 5, 2020 to consider whether to approve the Settlements and approve Class Counsel’s request of attorneys’ fees of up to 33% of the Settlement Funds, plus reimbursement of costs and expenses. Class Members or their own lawyers may appear and speak at the hearing at their own expense.
More information is available about the Settlements on the website, www.liborgreenpondsettlement.com , and in the Long Form Notice accessible on that website, or by calling 1-866-403-5447.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200624005032/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
